139 related articles for article (PubMed ID: 28814374)
21. Both triazolyl ester of ketorolac (15K) and YM155 inhibit the embryonic angiogenesis in ovo (fertilized eggs) via their common PAK1-survivin/VEGF signaling pathway.
Ahn MR; Bae JY; Jeong DH; Takahashi H; Uto Y; Maruta H
Drug Discov Ther; 2017; 11(6):300-306. PubMed ID: 29332887
[TBL] [Abstract][Full Text] [Related]
22. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
[TBL] [Abstract][Full Text] [Related]
23. Several herbal compounds in Okinawa plants directly inhibit the oncogenic/aging kinase PAK1.
Nguyen BC; Taira N; Tawata S
Drug Discov Ther; 2014 Dec; 8(6):238-44. PubMed ID: 25639302
[TBL] [Abstract][Full Text] [Related]
24. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Potential of Targeting PAK Signaling.
Senapedis W; Crochiere M; Baloglu E; Landesman Y
Anticancer Agents Med Chem; 2016; 16(1):75-88. PubMed ID: 26081410
[TBL] [Abstract][Full Text] [Related]
26. Frondoside A from sea cucumber and nymphaeols from Okinawa propolis: Natural anti-cancer agents that selectively inhibit PAK1 in vitro.
Nguyen BCQ; Yoshimura K; Kumazawa S; Tawata S; Maruta H
Drug Discov Ther; 2017 May; 11(2):110-114. PubMed ID: 28442678
[TBL] [Abstract][Full Text] [Related]
27. 1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice.
Hennig R; Albawardi A; Almarzooqi S; Haneefa S; Imbaraj E; Zaaba NE; Nemmar A; Subramanya S; Maruta H; Adrian TE
Drug Discov Ther; 2019 Nov; 13(5):248-255. PubMed ID: 31656252
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
29. Chemical composition and pharmacological properties of Macaranga-type Pacific propolis: A review.
Shahinozzaman M; Obanda DN; Tawata S
Phytother Res; 2021 Jan; 35(1):207-222. PubMed ID: 32776610
[TBL] [Abstract][Full Text] [Related]
30. p21-activated kinase 1: PAK'ed with potential.
Ong CC; Jubb AM; Zhou W; Haverty PM; Harris AL; Belvin M; Friedman LS; Koeppen H; Hoeflich KP
Oncotarget; 2011 Jun; 2(6):491-6. PubMed ID: 21653999
[TBL] [Abstract][Full Text] [Related]
31. A computational approach to explore and identify potential herbal inhibitors for the p21-activated kinase 1 (PAK1).
Shahinozzaman M; Ishii T; Ahmed S; Halim MA; Tawata S
J Biomol Struct Dyn; 2020 Aug; 38(12):3514-3526. PubMed ID: 31448698
[TBL] [Abstract][Full Text] [Related]
32. Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1.
Maruta H
Drug Discov Ther; 2011 Dec; 5(6):266-78. PubMed ID: 22466437
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.
Eswaran J; Li DQ; Shah A; Kumar R
Clin Cancer Res; 2012 Jul; 18(14):3743-9. PubMed ID: 22595609
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
Lee W; Crawford JJ; Aliagas I; Murray LJ; Tay S; Wang W; Heise CE; Hoeflich KP; La H; Mathieu S; Mintzer R; Ramaswamy S; Rouge L; Rudolph J
Bioorg Med Chem Lett; 2016 Aug; 26(15):3518-24. PubMed ID: 27346791
[TBL] [Abstract][Full Text] [Related]
35. Targeting PAK1.
Semenova G; Chernoff J
Biochem Soc Trans; 2017 Feb; 45(1):79-88. PubMed ID: 28202661
[TBL] [Abstract][Full Text] [Related]
36. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure-activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors.
Xu Y; Foulks JM; Clifford A; Brenning B; Lai S; Luo B; Parnell KM; Merx S; McCullar MV; Kanner SB; Ho KK
Bioorg Med Chem Lett; 2013 Jul; 23(14):4072-5. PubMed ID: 23756368
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of 2-indolinone derivatives as PAK1 inhibitors in MDA-MB-231 cells.
Yao D; Ruhan A; Jiang J; Huang J; Wang J; Han W
Bioorg Med Chem Lett; 2020 Sep; 30(17):127355. PubMed ID: 32738980
[TBL] [Abstract][Full Text] [Related]
39. Role of p-21-activated kinases in cancer progression.
King H; Nicholas NS; Wells CM
Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
[TBL] [Abstract][Full Text] [Related]
40. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.
Yi C; Maksimoska J; Marmorstein R; Kissil JL
Biochem Pharmacol; 2010 Sep; 80(5):683-9. PubMed ID: 20302846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
